TRPC1 and cyclic hematopoiesis: Finally, in CH rat model, topotecan, a toposisomerase inhibitor already used for cancer therapy, inhibits CH-induced TRPC1/4/6 overexpression and reduces [Ca2+]i in PASMC, improving hemodynamic parameters and attenuating artery remodeling and right ventricle hypertrophy [98].